04th May 2022
Consilium Strategic Communications advises OMass Therapeutics $100m Series B financing
London, 4 May 2022; Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is proud to have supported OMass Therapeutics in its recently announced $100m[1] (£75.5 million) Series B Financing to progress its drug pipeline. The international syndicate of top-tier life science specialists was led by new investors, GV, Northpond Ventures and Sanofi Ventures, with existing investors, Syncona, Oxford Science Enterprises and Oxford University also participating.
Originally spun out of Oxford University, OMass has commercialised Professor Dame Carol Robinson’s breakthrough research in native mass spectrometry to develop its proprietary drug discovery platform, OdyssION™. The platform integrates novel biochemistry techniques, next-generation native mass spectrometry, and custom chemistry, to allow for the interrogation of protein interactions within its native ecosystem while avoiding the confounding complexity of the cell. This delivers key benefits in the search for drugs against previously intractable targets. The proceeds of the financing will be used to advance OMass’ portfolio of programs in rare diseases and immunological conditions towards clinical trials.
“This significant fund raising is a testament to OMass’s capabilities in discovering new small molecule drugs against many important targets that have proved to be difficult or impossible to address. We congratulate Ros and the team on the fundraise and are proud to have worked with them to have communicated the news internationally,” said Chris Gardner PhD, Partner at Consilium Strategic Communications.
“The completion of this oversubscribed round with such high-calibre investors is recognition of the significance of our OdyssION™ platform and its potential to support the development of an exciting portfolio of novel drug candidates. It was a critical piece of news for the Company and in working with Consilium we have ensured it was seen by our key audiences around the world through excellent media coverage. It has been a pleasure working with the team,” said Ros Deegan, CEO of OMass.
The Consilium team representing OMass on the fund closing was Sue Charles, Chris Gardner and Kumail Waljee.
To view OMass’s announcement, please visit www.omass.com.
-ENDS-
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. Consilium's team, based in both Europe and US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision makers and executives on critical communications programmes, international media management, transactions and healthcare stakeholder challenges. Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to
discrete specialist reputation management projects. For more information please see www.consilium-comms.com.
About OMass Therapeutics
OMass Therapeutics is a biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes. The company’s unique OdyssION™ technology platform comprises novel biochemistry techniques, next-generation native mass spectrometry, and custom chemistry. This allows OMass to interrogate not just the target, but also the interaction of the target with its native ecosystem, separate from the confounding complexity of the cell. The result is cell-system fidelity with cell-free precision. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, therapeutics that target solute carriers, complex-bound proteins, and GPCRs.
Headquartered in Oxford, UK, OMass has raised over $150M (£119M) from a top-tier international investor syndicate, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, and Sanofi Ventures.
To learn more, please visit www.omass.com
[1] using FX at signed term sheet phase
